,40 Pharmacological inhibitors of PCSK9 lowering LDL-C levels and, thus, reducing the risk of coronary heart disease, were developed after the identification of healthy PCSK9 carriers, a process that could have been initiated by our analysis. The gene discussed is PCSK9; the disease is coronary artery disorder.